The pharmaceutical industry has been manufacturing cardiac medications for many years. The price of these medications continues to rise year in and year out. Insurance companies such as Blue Cross and Blue Shield has tried to put a cap on the amount of money that can be charged for medications such as Digoxin. The cost of cardiogenic medications has more than tripled as a result of increased coronary artery disease. We must continue to be proactive in the prevention of myocardial disease. Cardiac medications offer great importance but if there are unaffordable or benefits cannot be obtained.